SINGAPORE, Sept. 11, 2023 /PRNewswire/ — On September 9th, 2023, Biosyngen Pte Ltd (hereafter as “Biosyngen”) announced that the U.S. FDA has cleared the Investigational New Drug (IND) application for Phase I/II clinical trial of BRL03 for the treatment of lung cancer, gastric cancer and…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.